FACTS­:

(1) - Major regional partner to be announced including details of investment

(2) - Interem phase 2 results which should show we have the premier product in our field .

(3) - IPO of Immuno on the nasdaq of which we own 6% which will show a highly valued equity stake

 

So there you have 3 major facts for this stock to go alot higher in the very near term  - selling before all 3 are released would be foolish as new valuations will be put on the company -  along which should follow of numerous analyst coverage north and south of the border - Final phase 2 results in 6 months of which time we will almost certaintly be a buyout canidate. So those doubting this stock do you honestly believe this stock will not go alot higher  on these milestones .